Cytomegalovirus in Pediatric Hematopoietic Stem Cell Transplantation: A Case-Based Panel Discussion of Current Challenges

J Pediatric Infect Dis Soc. 2018 Dec 26;7(suppl_2):S72-S74. doi: 10.1093/jpids/piy104.

Abstract

Cytomegalovirus (CMV) remains a significant contributor to morbidity and death after pediatric solid and stem cell transplantation. Decisions regarding prevention and treatment often lack pediatric-specific data to drive decision making. We present here a case-based discussion around some of these specific topics and focus on approaches to CMV prevention, post-CMV secondary prophylaxis options, and identification and treatment of resistant CMV infection, including emerging antiviral agents and the use of cytotoxic CMV-specific T-cells, in the setting of pediatric hematopoietic stem cell transplantation.

Publication types

  • Case Reports

MeSH terms

  • Antiviral Agents / therapeutic use
  • Child
  • Cytomegalovirus / immunology
  • Cytomegalovirus Infections / complications
  • Cytomegalovirus Infections / prevention & control*
  • Cytomegalovirus Infections / virology
  • Drug Resistance, Viral
  • Fatal Outcome
  • Foscarnet / therapeutic use
  • Granulomatous Disease, Chronic / complications
  • Granulomatous Disease, Chronic / therapy*
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Male
  • Recurrence
  • Respiratory Insufficiency / etiology
  • Risk Assessment
  • Secondary Prevention
  • T-Lymphocytes, Cytotoxic
  • Valganciclovir / therapeutic use
  • Viral Load

Substances

  • Antiviral Agents
  • Foscarnet
  • Valganciclovir